Search

  • Select Article Type
  • Abstract Supplements
  • Blood Group Review
  • Call to Arms
  • Hypothesis
  • In Memoriam
  • Interview
  • Introduction
  • Letter to the Editor
  • Short Report
  • abstract
  • Abstracts
  • Article
  • book-review
  • case-report
  • case-study
  • Clinical Practice
  • Commentary
  • Conference Presentation
  • conference-report
  • congress-report
  • Correction
  • critical-appraisal
  • Editorial
  • Editorial Comment
  • Erratum
  • Events
  • Letter
  • Letter to Editor
  • mini-review
  • minireview
  • News
  • non-scientific
  • Obituary
  • original-paper
  • original-report
  • Original Research
  • Pictorial Review
  • Position Paper
  • Practice Report
  • Preface
  • Preliminary report
  • Product Review
  • rapid-communication
  • Report
  • research-article
  • Research Communicate
  • research-paper
  • Research Report
  • Review
  • review -article
  • review-article
  • review-paper
  • Review Paper
  • Sampling Methods
  • Scientific Commentary
  • short-communication
  • short-report
  • Student Essay
  • Varia
  • Welome
  • Select Journal
  • Immunohematology

 

Article | 17-February-2021

Clinical impacts of DNA-based typing and provision of antigen-matched red blood cell units for chronically transfused patients with thalassemia

Chronic transfusion in patients with thalassemia is often complicated by red blood cell (RBC) alloantibodies to the lacking antigens on the patients’ RBCs. The prevalence of alloantibodies ranges from 4.25 to 37 percent in patients with thalassemia.1–6 Clinically significant alloantibodies can shorten transfused erythrocyte survival due to hemolytic transfusion reactions. To reduce the alloantibody risk, RBC antigen serotyping for Rh (C, c, E, e) and MNS hybrid glycophorins, especially for MNS7

P. Watanaboonyongcharoen, S. Onspun, P. Rojnuckarin

Immunohematology, Volume 36 , ISSUE 4, 137–145

Report | 01-December-2019

Directed blood donor program decreases donor exposure for children with sickle cell disease requiring chronic transfusion

Dionna O. Roberts, Brittany Covert, Terianne Lindsey, Vincent Edwards, Lisa McLaughlin, John Theus, Ricardo J. Wray, Keri Jupka, David Baker, Mary Robbins, Michael R. DeBaun

Immunohematology, Volume 28 , ISSUE 1, 7–12

Article | 26-October-2019

HEA BeadChipTM technology in immunohematology

by BioArray Solutions (Immucor, Warren, NJ) is one of the commercial DNA array platforms currently available to predict HEAs by DNA analysis. This technology provides a useful tool to increase the inventory of antigen-negative RBC units and prevent immunization of patients who require chronic transfusion by providing compatible RBC units based on matching by DNA testing.

Cinzia Paccapelo, Francesca Truglio, Maria Antonietta Villa, Nicoletta Revelli, Maurizio Marconi

Immunohematology, Volume 31 , ISSUE 2, 81–90

Case report | 01-December-2019

Red blood cell phenotype matching for various ethnic groups

Patients requiring chronic transfusion support are at risk of alloimmunization after red blood cell (RBC) transfusion because of a disparity between donor and recipient antigen profiles. This research explored the probability of obtaining an exact extended phenotype match between blood donors randomly selected from our institution and patients randomly selected from particular ethnic groups. Blood samples from 1,000 blood donors tested by molecular method were evaluated for the predicted

Karafa S.W. Badjie, Craig D. Tauscher, Camille M. van Buskirk, Clare Wong, Sarah M. Jenkins, Carin Y. Smith, James R. Stubbs

Immunohematology, Volume 27 , ISSUE 1, 12–19

Report | 16-March-2020

D+ platelet transfusions in D– patients: cause for concern?

after transfusion. No patients were shown to make anti-D after platelet transfusion. There was no evidence of D alloimmunization as a result of transfusion of D+ platelets in any D– patient during this study. The data do not support the practice of restricting D– patients to receiving only D– apheresis platelets, even among patients with chronic transfusion requirements. Prophylactic use of RhIG for D+ apheresis platelet transfusions in D– patients also appears to be

Angela N. Bartley, John B. Carpenter, Mary P. Berg

Immunohematology, Volume 25 , ISSUE 1, 5–8

No Record Found..
Page Actions